Article
Engineering, Biomedical
Michael Super, Edward J. Doherty, Mark J. Cartwright, Benjamin T. Seiler, Fernanda Langellotto, Nikolaos Dimitrakakis, Des A. White, Alexander G. Stafford, Mohan Karkada, Amanda R. Graveline, Caitlin L. Horgan, Kayla R. Lightbown, Frank R. Urena, Chyenne D. Yeager, Sami A. Rifai, Maxence O. Dellacherie, Aileen W. Li, Collin Leese-Thompson, Hamza Ijaz, Amanda R. Jiang, Vasanth Chandrasekhar, Justin M. Scott, Shanda L. Lightbown, Donald E. Ingber, David J. Mooney
Summary: Injectable biomaterial vaccines designed to magnetically capture pathogen-associated molecular patterns protect mice and pigs against septic shock from lethal bacterial infections.
NATURE BIOMEDICAL ENGINEERING
(2022)
Review
Immunology
Pauline Schmitt, Lisa Borkner, Seyed Davoud Jazayeri, Karen N. McCarthy, Kingston H. G. Mills
Summary: Whooping cough, caused by Bordetella pertussis, remains a major global health concern. Current vaccines are effective in preventing severe disease but do not stop nasal infection and asymptomatic transmission. Animal studies have shown that these vaccines fail to elicit key immune responses necessary for sustained nasal immunity. Live-attenuated or novel adjuvant-based vaccines that induce specific immune cell responses in the respiratory tract show promise as next-generation pertussis vaccines.
CURRENT OPINION IN IMMUNOLOGY
(2023)
Article
Immunology
Marta Prygiel, Ewa Mosiej, Karol Wdowiak, Paulina Gorska, Maciej Polak, Klaudia Lis, Katarzyna Krysztopa-Grzybowska, Aleksandra Anna Zasada
Summary: The aim of the study was to compare the elimination of different genotypes of Bordetella pertussis isolates with various vaccines, revealing a potential genomic adaptation of the bacteria due to vaccine selection pressure in high vaccination coverage populations. Additionally, pertactin-negative isolates were suspected to reduce vaccine effectiveness. The study also showed that the most effective vaccine was the experimental one with a composition identical to the strains used for infection, indicating potential differences in phenotypes between circulating isolates and vaccine strains.
MEDICAL MICROBIOLOGY AND IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Cheryl Keech, Vicki E. Miller, Barbara Rizzardi, Christopher Hoyle, Melinda J. Pryor, Jonathan Ferrand, Ken Solovay, Marcel Thalen, Stephanie Noviello, Peter Goldstein, Andrew Gorringe, Breeze Cavell, Qiushui He, Alex-Mikael Barkoff, Keith Rubin, Camille Locht
Summary: BPZE1, a live attenuated intranasal pertussis vaccine, induces nasal mucosal immunity and functional serum responses. This study demonstrates the potential of BPZE1 to prevent pertussis infection, leading to reduced transmission and diminished epidemic cycles.
Article
Immunology
Han Xu, Jing Huang, Zhaolu Liu, Xin Li, Kangfeng Wang, Erling Feng, Jun Wu, Li Zhu, Kaihu Yao, Chao Pan, Hengliang Wang
Summary: The study developed new pertussis vaccine candidates by fusing pertussis antigens with immune-boosting carrier proteins, which significantly increased the immune protection in mice against pertussis and showed promising prophylactic effects in challenge experiments. This B5 subunit-based vaccine strategy provides a potential option for vaccine design.
Article
Immunology
Pedro Plans-Rubio
Summary: A study conducted in 2019 assessed vaccination coverage for 13 routine vaccines, as well as immunity levels against measles and pertussis. The findings revealed that many countries had vaccination coverage below the target of 90%, with some vaccines experiencing a decline in coverage since 2015.
Article
Chemistry, Multidisciplinary
Shuxiong Chen, Diana H. Quan, Xiaonan T. Wang, Sarah Sandford, Joanna R. Kirman, Warwick J. Britton, Bernd H. A. Rehm
Summary: Current tuberculosis vaccines do not consistently protect against the disease, prompting the need for new and improved vaccines. Research has shown that mycobacterial antigen fusions assembled into particulate vaccines can induce long-lasting antigen-specific T cell responses and protective immunity in mice challenged with virulent Mycobacterium tuberculosis. This study demonstrated that polyester nanoparticles displaying the mycobacterial antigen fusion H4 can offer a level of protection in the lungs comparable to the currently approved TB vaccine, making it a promising subunit vaccine candidate for cost-effective manufacturing and efficient protection against TB.
Review
Immunology
Zhongjie Sun, Tingxin Wu, Huangfan Xie, Yuhuan Li, Jinlan Zhang, Xuncheng Su, Hailong Qi
Summary: This review discusses the role of cellular immunity in fighting against COVID-19 and summarizes recent advances in the development of SARS-CoV-2 vaccines and the immune responses induced by vaccines, aiming to improve the design of new vaccines and immunization strategies.
Review
Immunology
Tuck-Weng Kok, Angelo A. A. Izzo, Maurizio Costabile
Summary: Virus neutralization at respiratory mucosal surfaces is crucial for preventing infection. While extracellular secretory immunoglobulin A (sIgA) has been well-studied, the protective role of intracellular specific IgA (icIgA) is not well defined. Previous studies have shown that icIgA can neutralize several viruses, and recent research has focused on its role in influenza and other respiratory infections. Further understanding of icIgA neutralization mechanisms will inform the development of effective mucosal vaccines.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2023)
Review
Immunology
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Sakirul Khan
Summary: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a devastating global pandemic with millions of reported cases and deaths. Vaccines and antiviral drugs have been developed to combat COVID-19, and there is potential for further improvement. COVID-19 is a virus-induced, immune-mediated pathological process, and the severity of the disease is influenced by host immune responses. The role of vaccines, long-term persistence of SARS-CoV-2 infection, and the varied manifestations of COVID-19 have generated numerous questions among populations, policymakers, physicians, and scientists.
Review
Immunology
Bahaa Abu-Raya, Kevin Forsyth, Scott A. Halperin, Kirsten Maertens, Christine E. Jones, Ulrich Heininger, Daniela Hozbor, Carl Heinz Wirsing von Koenig, Amar J. Chitkara, Rudzani Muloiwa, Tina Q. Tan
Summary: Vaccination against pertussis in pregnancy has emerged as an ideal strategy to protect infants from severe morbidity and mortality. The Global Pertussis Initiative held a meeting to discuss the scientific literature supporting this vaccination approach and provided consensus statements on behalf of the initiative.
Review
Biochemistry & Molecular Biology
Bahaa Abu-Raya, Mirjam J. Esser, Eve Nakabembe, Jesus Reine, Kyle Amaral, Annieck M. Diks, Esther Imede, Sing Sing Way, Ali M. Harandi, Andrew Gorringe, Kirsty Le Doare, Scott A. Halperin, Magdalena A. Berkowska, Manish Sadarangani
Summary: Neither immunization nor recovery from natural infection provides life-long protection against Bordetella pertussis. Replacement of a whole-cell pertussis (wP) vaccine with an acellular pertussis (aP) vaccine, mutations in B. pertussis strains, and better diagnostic techniques contribute to the resurgence of the number of cases especially in young infants. Development of new immunization strategies relies on a comprehensive understanding of the immune system responses to infection and immunization and how triggering these immune components would ensure protective immunity.
JOURNAL OF MOLECULAR BIOLOGY
(2023)
Article
Microbiology
Yanfang Zhang, Xinrui Kang, Sheng Liu, Pu Han, Wenwen Lei, Ke Xu, Zepeng Xu, Zhengrong Gao, Xuemei Zhou, Yaling An, Yuxuan Han, Kefang Liu, Xin Zhao, Lianpan Dai, Peiyi Wang, Guizhen Wu, Jianxun Qi, Kun Xu, George F. Gao
Summary: In this study, researchers designed and developed a COVID-19 vaccine using RBD heterotrimers as the immunogen. The vaccine was shown to induce broad immune responses and provide protection against SARS-CoV-2 variants. This study provides guidance for future vaccine design.
Article
Immunology
Colleen J. Sedney, Amanda Caulfield, Kaylan K. Dewan, Uriel Blas-Machado, Maiya Callender, Nancy R. Manley, Eric T. Harvill
Summary: The increased susceptibility of neonates to specific pathogens has previously been attributed to an underdeveloped immune system. More recent data suggest neonates have effective protection against most pathogens but are particularly susceptible to those that target immune functions specific to neonates. Bordetella pertussis (Bp), the causative agent of whooping cough, causes more serious disease in infants attributed to its production of pertussis toxin (PTx), although the neonate-specific immune functions it targets remain unknown. The study found that neonatal mice from five to eight days old are more susceptible to Bp than slightly older mice, and they can effectively respond to and control Bp lacking PTx. PTx efficiently blocks some very effective form(s) of neonatal protective immunity, potentially providing a tool to better understand the neonatal immune system. The results also demonstrate a striking age-dependent response to Bp and define an early age of extreme susceptibility to Bp. The study's findings may be useful in studying other pathogens that primarily infect neonates and PTx may prove a particularly valuable tool for probing the poorly understood neonatal immune system.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Peng Wang, Sherif Ramadan, Purnima Dubey, Rajendar Deora, Xuefei Huang
Summary: This article discusses the development of pertussis vaccines and their limitations, emphasizing the need for new vaccines to protect against the disease and prevent carrier development, reducing transmission. The lipo-oligosaccharide of the Bordetella pertussis bacterium is an attractive antigen for vaccine development due to its potential bactericidal activities. However, obtaining the saccharide on a large scale with high purity remains a major obstacle. Chemical synthesis offers a complementary approach to accessing carbohydrate epitopes in a pure and structurally well-defined form. The first total synthesis of the non-reducing end pertussis pentasaccharide is discussed, along with its conjugation to a powerful immunogenic carrier, bacteriophage Q beta, resulting in high levels and long-lasting anti-glycan IgG antibodies. This paves the way for the development of a new generation of anti-pertussis vaccines with high bactericidal activities and biocompatibilities.
BIOORGANIC & MEDICINAL CHEMISTRY
(2022)
